Trial Profile
Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Fosamprenavir (Primary) ; Posaconazole (Primary) ; Ritonavir (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- Acronyms EPOS
- 28 Jul 2010 Results have been published in the Journal of Antimicrobial Chemotherapy.
- 19 Feb 2010 Results presented at the 17th Conference on Retroviruses and Opportunistic Infections (CROI).
- 09 Dec 2009 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.